IWWM-11 2022 | Therapeutic options available to patients with R/R Waldenström’s macroglobulinemia
In this video, Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, summarizes therapeutic options available to patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia (WM), including chemoimmunotherapy, Bruton’s tyrosine kinase (BTK) inhibitors, and bortezomib. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards
